AZD5438 in Patients With Advanced Solid Malignancies

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00088790
First received: August 4, 2004
Last updated: January 25, 2011
Last verified: January 2011

August 4, 2004
January 25, 2011
July 2004
December 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00088790 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
AZD5438 in Patients With Advanced Solid Malignancies
Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Not Provided
Interventional
Phase 1
Primary Purpose: Treatment
Neoplasms
Drug: AZD5438
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
December 2005
December 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Advanced solid malignancy
  • Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

  • Radiotherapy within 3 weeks of the start of treatment
  • Investigational product within the last 3 weeks
  • Systemic cytotoxic anti-cancer therapy within the last 3 weeks
  • Any significant clinical disorder that makes it undesirable for the patient to participate
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00088790
D0110C00005
Not Provided
Not Provided
AstraZeneca
Not Provided
Not Provided
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP